<DOC>
	<DOC>NCT02753803</DOC>
	<brief_summary>A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone 30 mg after oral administration in healthy male subjects</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg</brief_title>
	<detailed_description>A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Healthy Male Volunteers (Age: 19~45years) 55&lt;Body Weight&lt;90, 18&lt;BMI&lt;27 FPG: 70125 mg/dL galactose intolerance, Lapp lactase deficiency, glucosegalactose malabsorption Clinically significant Medical History Allergy or Drug Hypersensitivity AST(SGOT), ALT(SGPT) &gt; Upper Normal Range*1.5, eGFR&lt;80 mL/min Drink during clinical trial period Smoking during clinical trial period Grapefruit/Caffeine intake during clinical trial period No Contraception</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>